Capricor Therapeutics logo
Capricor Therapeutics CAPR
$ 27.93 0.14%

Quarterly report 2025-Q3
added 11-10-2025

report update icon

Capricor Therapeutics Net Debt 2011-2026 | CAPR

Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]

Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.

Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.

Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.

Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.

Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.

Annual Net Debt Capricor Therapeutics

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
-12.5 M -7.04 M -32 M -32.3 M -523 K -883 K -6.14 M 23.7 M 11.6 M 1.12 M 2.56 M -46.7 K -1.04 M

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
23.7 M -32.3 M -4.12 M

References

  1. Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.

Net Debt of other stocks in the Biotechnology industry

Issuer Net Debt Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
163 M - 2.43 % $ 254 M germanyGermany
Acer Therapeutics Acer Therapeutics
ACER
-2.08 M - 2.71 % $ 14 M usaUSA
AbbVie AbbVie
ABBV
59.5 B $ 232.08 3.29 % $ 411 B usaUSA
AbCellera Biologics AbCellera Biologics
ABCL
14.7 M $ 3.61 0.56 % $ 1.08 B canadaCanada
Abeona Therapeutics Abeona Therapeutics
ABEO
-9.07 M $ 5.12 -1.54 % $ 109 M usaUSA
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
-107 M $ 4.66 -0.85 % $ 773 M canadaCanada
ACADIA Pharmaceuticals ACADIA Pharmaceuticals
ACAD
-83 M $ 24.56 -0.32 % $ 4.07 B usaUSA
I-Mab I-Mab
IMAB
-1.06 B - - $ 866 M chinaChina
Achieve Life Sciences Achieve Life Sciences
ACHV
-15.5 M $ 4.56 -3.59 % $ 90.4 M usaUSA
AC Immune SA AC Immune SA
ACIU
-191 M $ 2.93 -1.01 % $ 229 M schweizSchweiz
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
-402 M - - $ 40.3 B usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
12.6 M - -10.17 % $ 12.2 K usaUSA
Aclaris Therapeutics Aclaris Therapeutics
ACRS
-17.8 M $ 2.87 -8.31 % $ 352 M usaUSA
Biophytis SA Biophytis SA
BPTS
-4.01 M - -13.47 % $ 169 M franceFrance
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
-30.2 M - - $ 1.01 B usaUSA
Adagene Adagene
ADAG
-71 M $ 2.96 -4.67 % $ 167 M chinaChina
ADC Therapeutics SA ADC Therapeutics SA
ADCT
-459 M $ 4.1 -0.73 % $ 105 M schweizSchweiz
Adial Pharmaceuticals Adial Pharmaceuticals
ADIL
-5.85 M $ 2.53 - $ 16.4 M usaUSA
ADMA Biologics ADMA Biologics
ADMA
-17.2 M $ 15.57 2.57 % $ 3.71 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
-36 M - - $ 26.5 M usaUSA
Adaptive Biotechnologies Corporation Adaptive Biotechnologies Corporation
ADPT
65 M $ 16.02 -2.67 % $ 2.43 B usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
-824 K - -1.52 % $ 24.7 M usaUSA
ADiTx Therapeutics ADiTx Therapeutics
ADTX
287 K $ 0.46 -4.63 % $ 6.06 K usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
-6.17 M - -18.52 % $ 27.3 M britainBritain
Agenus Agenus
AGEN
-60.8 M $ 3.33 -0.89 % $ 1.19 M usaUSA
Agios Pharmaceuticals Agios Pharmaceuticals
AGIO
-48.9 M $ 30.23 0.83 % $ 1.75 B usaUSA
AIM ImmunoTech AIM ImmunoTech
AIM
-26.2 M $ 0.91 -8.59 % $ 43.8 M usaUSA
Akebia Therapeutics Akebia Therapeutics
AKBA
-133 M $ 1.31 -0.76 % $ 337 M usaUSA
Akari Therapeutics, Plc Akari Therapeutics, Plc
AKTX
-5.45 M $ 0.24 -8.87 % $ 5.73 B britainBritain
ARCA biopharma ARCA biopharma
ABIO
-60.6 M - 1052.0 % $ 415 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
114 M - -24.86 % $ 820 K usaUSA
Acasti Pharma Acasti Pharma
ACST
-27.4 M - 4.01 % $ 150 M canadaCanada
Aldeyra Therapeutics Aldeyra Therapeutics
ALDX
-129 M $ 5.46 -0.73 % $ 328 M usaUSA
Alector Alector
ALEC
-47.4 M $ 2.43 -5.08 % $ 250 M usaUSA
Aligos Therapeutics Aligos Therapeutics
ALGS
-132 M $ 7.03 -6.27 % $ 452 M usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
31.1 M - - $ 86.2 M usaUSA
Alkermes plc Alkermes plc
ALKS
-319 M $ 30.1 -2.05 % $ 4.96 B irlandaIrlanda
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
246 M - - - russiaRussia
Allogene Therapeutics Allogene Therapeutics
ALLO
12 M $ 2.78 1.83 % $ 436 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
-1.04 M - 1.93 % $ 17.4 M usaUSA
Alnylam Pharmaceuticals Alnylam Pharmaceuticals
ALNY
-604 M $ 332.92 0.51 % $ 43.6 B usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
-340 M - - $ 3.67 B usaUSA
Akouos Akouos
AKUS
-92.9 M - 0.23 % $ 488 M usaUSA
Altimmune Altimmune
ALT
-35.2 M $ 4.31 -3.36 % $ 306 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
-239 M - -0.23 % $ 916 M usaUSA
ALX Oncology Holdings ALX Oncology Holdings
ALXO
-7.15 M $ 2.11 -10.21 % $ 110 M usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
-29.5 M - 3.16 % $ 1.9 M usaUSA
Amgen Amgen
AMGN
41 B $ 388.16 2.33 % $ 209 B usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
-3.44 M - 10.36 % $ 9.8 M usaUSA
AlloVir AlloVir
ALVR
-62.7 M - 4.14 % $ 49.1 M usaUSA